Rhumbline Advisers Next Cure, Inc. Transaction History

Rhumbline Advisers

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	BUY	$1.47 - $1.86 $1,033 - $1,307	703 New	703 $1,000
Q2 2021 Aug 05, 2021	SELL	$7.6 - $10.28 $141,770 - $191,763	-18,654 Closed	0 $0
Q1 2021 May 06, 2021	SELL	$9.81 - $13.88 $7,995 - $11,312	-815 Reduced 4.19%	18,654 $187,000
Q4 2020 Feb 10, 2021	BUY	$9.47 - $12.43 $12,898 - $16,929	1,362 Added 7.52%	19,469 $212,000
Q3 2020 Nov 12, 2020	SELL	$8.15 - $21.17 $23,635 - $61,393	-2,900 Reduced 13.8%	18,107 $159,000
Q2 2020 Aug 13, 2020	BUY	$21.19 - $40.2 $77,173 - $146,408	3,642 Added 20.97%	21,007 $450,000
Q1 2020 May 06, 2020	BUY	$32.32 - $58.37 $54,006 - $97,536	1,671 Added 10.65%	17,365 $644,000
Q4 2019 Feb 05, 2020	BUY	$25.0 - $92.22 $392,350 - $1.45 Million	15,694 New	15,694 $884,000

15.9M

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $36.4M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.